GlassScriptPhysician profile
Dan S Zuckerman
NPI 1023093507
$2,537.83
in general payments reported to CMS, 2019-2025
11 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.25 · 2020: $55.06 · 2021: $11.92 · 2022: $68.02 · 2023: $134 · 2024: $182 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,010 · Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,010.00 |
| Food and Beverage | $359.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,010.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $306.75 | 2019-2025 | Opdivo |
| Amgen INC. | $106.54 | 2024 | Imdelltra (Amg 757) |
| Intuitive Surgical, INC. | $75.25 | 2024 | |
| Genentech, INC. | $14.58 | 2025 | Tecentriq |
| Janssen Biotech, INC. | $12.79 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.